<DOC>
	<DOCNO>NCT00142467</DOCNO>
	<brief_summary>The purpose study test safety bevacizumab give combination gemcitabine oxaliplatin see effect ( good bad ) patient hepatocellular carcinoma .</brief_summary>
	<brief_title>Gemcitabine , Oxaliplatin Combination With Bevacizumab Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>- Treatment give cycle , cycle ( except cycle 1 ) 4 week long . Cycle 1 2 week long . - During cycle one , bevacizumab give intravenously day one . Two week receive bevacizumab , patient return clinic treatment 3 study drug . - During cycle 2 every cycle thereafter patient receive ; bevacizumab intravenously day one day 15 ; gemcitabine intravenously day 2 day 16 ; oxaliplatin intravenously day 2 day 16 . - The following evaluation conduct day 1 day 15 cycle ( every 2 week ) : physical examination , vital sign , medical history , blood test urine test . - Tumor measurement do CT and/or MRI repeat end cycle 3 every 2 cycle thereafter . - Dynamic Contrast-Enhanced Magnetic Resonance Imaging ( DCE-MRI ) liver Perfusions CT scan also do day 10-12 follow bevacizumab treatment cycle 1 , Perfusion CT repeat end cycle 3 . - Once study treatment stop follow evaluation perform : physical exam , vital sign , blood work , urine test , CT scan chest , abdomen pelvis , tumor measurement CT MRI scan . - Follow-up consist physical examination blood test every 6 month . - Patients continue receive study treatment long disease progression unacceptable side affect .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Unresectable metastatic hepatocellular carcinoma Measurable tumor Adequate hepatic function : total bilirubin &lt; 3.0mg/dl ; AST &lt; 7x ULN Adequate bone marrow function : ANC &gt; 1,000/mm3 ; platelet &gt; 75,000/mm3 INR &lt; 1.5 anticoagulation Up two prior chemotherapy regimens hepatocellular carcinoma 18 year age old ECOG performance status 01 Life expectancy &gt; 12 week Clinically apparent central nervous system metastases carcinomatous meningitis Uncontrolled serious medical psychiatric illness Pregnant lactate woman Current recent ( within 4 week first study infusion ) participation experimental study drug Uncontrolled hypertension Significant proteinuria Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Unresectable hepatocellular carcinoma</keyword>
	<keyword>Metastatic hepatocellular carcinoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>Avastin</keyword>
</DOC>